Clinical Trials Logo

Clinical Trial Summary

The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of CD19 positive Relapsed or Refractory acute lymphoblastic leukemia.


Clinical Trial Description

The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of CD19 positive Relapsed or Refractory acute lymphoblastic leukemia. The study consists of screening period (8 weeks), treatment period (4 weeks), and follow-up period (2 years at most). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04684147
Study type Interventional
Source Juventas Cell Therapy Ltd.
Contact Yan Zhou
Phone +86-15010390127
Email zhouyan@juventas.cn
Status Recruiting
Phase Phase 2
Start date December 24, 2020
Completion date December 31, 2026

See also
  Status Clinical Trial Phase
Completed NCT04230473 - A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia Phase 1
Terminated NCT01887587 - Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia Phase 1
Recruiting NCT03018093 - A Phase I Study Evaluating Safety and Efficacy of C-CAR011 Treatment in Adult Subjects With r/r CD19+B-ALL Phase 1
Recruiting NCT04825496 - Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia Phase 1
Not yet recruiting NCT06367114 - Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration) Phase 2